Ligand Announces Investment in Dianomi Therapeutics
Ligand Partner Seelos Therapeutics Becomes a Public Company
Ligand to Report Fourth Quarter and Full Year 2018 Results on February 7th
Ligand Introduces 2019 Financial Outlook and Raises 2018 Financial Guidance
Ligand Acquires Milestone and Royalty Rights to PTX-022 from Palvella Therapeutics
Ligand Announces OmniAb® Partnership with iMetabolic Biopharma Corporation
Ligand Reports Third Quarter 2018 Financial Results
Ligand to Participate in Stephens NY Investment Conference
Ligand to Report Third Quarter 2018 Results on November 8th
